에이비프로바이오
■■■ (외신)중화항체 후보물질 오미크론 변이에 중화작용
gurastock1
조회543
미반영 외신
[에이비프로바이오]
<o:p></o:p>
美 자회사 에이비프로, 중화항체 후보물질 ‘ABP310’ 오미크론 변이에 중화작용 유지
<o:p></o:p>
Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant
December 09, 2021 08:00 ET
<o:p></o:p>
WOBURN, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today shared an assessment of its neutralizing antibody candidate, ABP 310’s ability to neutralize the emerging SARS-CoV-2 Omicron variant. ABP 310 was studied against all currently prevalent and emerging SARS-CoV-2 variants of concern, including Omicron and Delta, and SARS-CoV, in a completed preclinical study. Based on evidence currently available from the study, the mutations in the Omicron variant do not escape binding and neutralization by ABP 310.
전문가방송
1/3
연관검색종목 04.20 11:00 기준
0/1000 byte